Blog
Perspectives and insights from the Verge team.
Why We Invested in Understanding Zoe
Verge HealthTech Fund outlines its investment in Understanding Zoe, an AI-native platform that transforms complex diagnostic data into actionable daily coaching for the parents, educators, and therapists of neurodivergent children.
Why We Invested in Zoundream
Verge HealthTech Fund explains its investment in Zoundream, a company developing an AI-powered solution that analyzes infant cries to translate their needs and early developmental signals, allowing juvenile brands and parents to better monitor infant health.
Why We Invested in Bot MD
Verge HealthTech Fund outlines its investment in Bot MD, a chat-first platform that embeds AI agents into popular messaging apps like WhatsApp and Viber to automate clinical workflows and patient communication. By eliminating the need for app downloads, the platform reduces administrative burdens for overstressed healthcare workers and improves patient care continuity across Southeast Asia.
Why We Invested in OLI
Verge HealthTech Fund outlines its investment in OLI, a company developing a portable, water-efficient home hemodialysis machine that bypasses traditional infrastructure constraints to expand renal care access in both developed and emerging markets.
Why We Invested in Lifeyear
Verge HealthTech Fund outlines its investment in Lifeyear, a UK-Estonian healthtech startup whose smartphone-enabled remote patient management platform delivers at-home digital cardiovascular care to reduce waiting times and ease health system burdens.
Why We Invested in Macuject
Verge HealthTech Fund outlines its investment in Macuject, an intelligent clinical workflow platform that analyzes retinal scans and tracks fluid changes to help specialists standardise treatment decisions and prevent vision loss from macular degeneration.
Why We Invested in CareLoop
Verge explains its thesis on CareLoop, a digital therapeutic for serious mental illness, beginning with psychosis and schizophrenia. The article frames the bet within Verge's longstanding conviction about the transformative potential of digital therapeutics.
Why We Invested in Prosoma
This article explains why Verge backed Prosoma, a digital-therapeutics company addressing oncological mental health, a deeply underserved space. Cancer is as much an emotional battle as a physical one. Traditional care leaves a gap, and that's exactly where Prosoma comes in.
Why We Invested In Endiatx
Verge HealthTech Fund outlines its investment in Endiatx, maker of ingestible robotic devices for inside-the-body diagnostics. It frames sci-fi-seeming medical technologies, from early neurodegeneration detection to camera-based vital-sign sensing, as becoming reality.
Why We Invested in Hello Inside
Verge HealthTech Fund outlines its investment in Hello Inside, an Austrian startup that pairs continuous glucose monitors with an AI-driven app to provide personalized, hormone-aware metabolic health coaching for women.
Why We Invested in BrainCapture
Verge explains its investment rationale for BrainCapture, addressing a critical gap in neurological diagnostics by making EEG more accessible for conditions such as epilepsy, particularly in resource-limited settings.
Why We Invested In Nostra:Biome
Verge HealthTech Fund outlines its investment in Nostra:Biome, an AI-powered platform that analyzes gut microbiome and lifestyle data to provide personalized, actionable recommendations aimed at driving Inflammatory Bowel Disease (IBD) into full remission.
Why We Invested In Sooma Medical
Verge HealthTech Fund outlines its investment in Sooma Medical, a Finnish company offering a non-invasive, at-home neuromodulation device that provides a side-effect-free therapy option for patients struggling with depression and chronic pain.
Why We Invested in Pathway
Verge HealthTech Fund outlines its investment in Pathway, an AI-native clinical decision support platform that synthesizes complex medical guidelines and data into a mobile-first reference tool for clinicians worldwide.
Why We Invested In ViewMind
Verge HealthTech Fund outlines its investment in ViewMind, a digital health company that pairs VR headsets with precise eye-tracking and AI algorithms to non-invasively diagnose and monitor neurodegenerative disorders years before symptoms appear.
The World's Largest Medical Tradeshow
Dr. Joseph Mocanu writes that Arab Health in Dubai is truly the world's largest medical tradeshow, serving as the ultimate global epicenter for healthcare innovators, startups, and investors.
Healthy Governance, Healthy Returns
Drawing on a talk at the APEC Business Ethics for SMEs Forum, this essay by Dr. Joseph Moccanu connects sound corporate governance with stronger financial returns.
Stop Pitchin'
Dr. Joseph Mocanu delivers a critique of the conventional startup-pitch ritual and a guide to how founders can stand out and extract more value from meetings with VCs.
Paging Doctor Koi
Verge HealthTech Fund outlines its investment in Doctor Koi, a Bangladeshi digital health startup whose flagship software, Digital RX, reduces medical errors by allowing physicians to easily digitize and manage their prescription-writing workflows.
Rwanda: The Singapore of Africa?
Dr. Joseph Mocanu details his eight-day trip to Rwanda to evaluate its potential as a highly organized, tech-forward gateway for innovation, drawing parallels to Singapore's economic model to assess how the country can anchor global healthtech scaling across the African continent.
Realising the promise of true telemedicine
Dr. Joseph Mocanu discusses Verge HealthTech Fund's commitment to universal healthcare access, exploring how true telemedicine must evolve beyond basic video consultations into integrated, scalable platforms that sustainably bridge critical care gaps in underserved global markets.
The long-held promise of point of care diagnostics
Dr. Joseph Mocanu discusses how point-of-care diagnostics influence the vast majority of medical decisions, exploring the tech's long-standing potential to decentralize testing and improve patient outcomes by moving lab-grade analysis directly to the patient's side.
The Need For Coordination of Health Data and Sweet Tropical Fruits
Dr. Joseph Mocanu discusses the critical need for global healthcare data standards (like FHIR), drawing a clever parallel to how the export industry successfully standardized the classification of sweet tropical fruits to show that unifying fragmented health systems is entirely a matter of proper coordination.
Reflections On Raising Our First VC Fund
Dr. Joseph Mocanu reflects on the intense journey of raising Verge HealthTech's inaugural fund, sharing key milestones, the lessons learned from navigating investor pitches, and the strategy that ultimately allowed them to build momentum and achieve their final close.
Global Healthcare Data Standards: A Matter of Time?
Dr. Joseph Mocanu argues that universal healthcare data standards are a matter of when, not if, drawing an analogy to the web and data-delivery standards that already move content seamlessly.
Reflections on the Family We Choose
Dr. Joseph Mocanu reflects on the concept of "the family we choose," exploring how shared values, mutual trust, and long-term commitment define the core relationships between venture capital investors and the founders they choose to back
Mental Health: Where Do We Begin?
Dr. Joseph Mocanu addresses the global mental health crisis, exploring the baseline hurdles of stigma, diagnosis, and care shortages while outlining how scalable digital health innovations must be deployed to fundamentally reshape the treatment landscape.
Breathing Easy: Why We Invest in Lung Health
Verge HealthTech Fund explains its thesis for investing in pulmonary solutions, highlighting that while respiratory conditions affect hundreds of millions of people worldwide and cause millions of deaths annually, scalable digital health and deeptech innovations present a massive opportunity to dramatically improve global lung care.
An Uber Insight Into The Uninsured
Dr. Joseph Mocanu uses an anecdote about an uninsured Uber driver, proud of being uninsured despite a costly accident, as a lens on the absurdities of the US healthcare system and the prospects for real reform.
Why We Do What We Do
Dr. Joseph Mocanu outlines the foundational mission and core philosophy behind Verge HealthTech Fund, explaining the driving purpose that motivates their focus on early-stage healthtech investments to solve global healthcare access, quality, and affordability challenges.
The Promise and Importance of Early Dementia Diagnosis
Dementia is a devastating, costly disease with a growing global burden, especially in Asia. Because effective treatment requires early intervention before symptoms appear, costly or invasive testing has limited prevention. To solve this, RetiSpec is developing an affordable, accessible eye-scan technology to screen for early dementia risk during routine checkups.
No posts match your search.